| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial
|
Lee, Nancy Y
|
|
2012
|
13 |
2 |
p. 172-180
9 p.
|
artikel
|
| 2 |
Analysis affirms secondary cancer risk with lenalidomide
|
Guha, Malini
|
|
2012
|
13 |
2 |
p. e54-
1 p.
|
artikel
|
| 3 |
Arrests in USA over unapproved stem-cell therapies
|
Furlow, Bryant
|
|
2012
|
13 |
2 |
p. e55-
1 p.
|
artikel
|
| 4 |
A STEPP too far for FLEX?
|
Bergot, Emmanuel
|
|
2012
|
13 |
2 |
p. e51-
1 p.
|
artikel
|
| 5 |
A STEPP too far for FLEX? – Authors' reply
|
Pirker, Robert
|
|
2012
|
13 |
2 |
p. e51-
1 p.
|
artikel
|
| 6 |
A tale of two tumours and a plea for progress
|
Fisher, Rosalie
|
|
2012
|
13 |
2 |
p. 124-125
2 p.
|
artikel
|
| 7 |
Biliary-tract cancer: improving therapy by adding molecularly targeted agents
|
Jensen, Lars Henrik
|
|
2012
|
13 |
2 |
p. 118-119
2 p.
|
artikel
|
| 8 |
Birth defects in offspring of cancer survivors investigated
|
Burki, Talha Khan
|
|
2012
|
13 |
2 |
p. e53-
1 p.
|
artikel
|
| 9 |
Cancer risk in patients with myotonic muscular dystrophy
|
Bennet, Neil
|
|
2012
|
13 |
2 |
p. e53-
1 p.
|
artikel
|
| 10 |
Cancer strategy in the UK: 1 year on
|
Burki, Talha Khan
|
|
2012
|
13 |
2 |
p. e52-
1 p.
|
artikel
|
| 11 |
Chordoma: current concepts, management, and future directions
|
Walcott, Brian P
|
|
2012
|
13 |
2 |
p. e69-e76
nvt p.
|
artikel
|
| 12 |
Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial
|
Bourhis, Jean
|
|
2012
|
13 |
2 |
p. 145-153
9 p.
|
artikel
|
| 13 |
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial
|
Chen, Lei
|
|
2012
|
13 |
2 |
p. 163-171
9 p.
|
artikel
|
| 14 |
Consensus-based standards for best supportive care in clinical trials in advanced cancer
|
Zafar, S Yousuf
|
|
2012
|
13 |
2 |
p. e77-e82
nvt p.
|
artikel
|
| 15 |
Don't pick the loser: lessons from the GeparQuinto trial
|
Chia, Stephen K
|
|
2012
|
13 |
2 |
p. 112-113
2 p.
|
artikel
|
| 16 |
Easing acceleration of head and neck chemoradiotherapy
|
Haigentz Jr, Missak
|
|
2012
|
13 |
2 |
p. 113-115
3 p.
|
artikel
|
| 17 |
Erratum
|
|
|
2012
|
13 |
2 |
p. e49-
1 p.
|
artikel
|
| 18 |
Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study
|
Lee, Jeeyun
|
|
2012
|
13 |
2 |
p. 181-188
8 p.
|
artikel
|
| 19 |
Infection risk not increased with alemtuzumab
|
Furlow, Bryant
|
|
2012
|
13 |
2 |
p. e57-
1 p.
|
artikel
|
| 20 |
Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study
|
Gotlieb, Walter H
|
|
2012
|
13 |
2 |
p. 154-162
9 p.
|
artikel
|
| 21 |
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial
|
Untch, Michael
|
|
2012
|
13 |
2 |
p. 135-144
10 p.
|
artikel
|
| 22 |
Medical paternalism: who knows best?
|
Corn, Benjamin W
|
|
2012
|
13 |
2 |
p. 123-124
2 p.
|
artikel
|
| 23 |
Medikidz explain cancer
|
Jouret, Jill
|
|
2012
|
13 |
2 |
p. 131-
1 p.
|
artikel
|
| 24 |
Mixed messages from US cancer report
|
Furlow, Bryant
|
|
2012
|
13 |
2 |
p. e54-
1 p.
|
artikel
|
| 25 |
Nasopharyngeal cancer: a promising future
|
Wee, Joseph
|
|
2012
|
13 |
2 |
p. 116-118
3 p.
|
artikel
|
| 26 |
NICE guidance on dasatinib, high-dose imatinib, and nilotinib for patients with CML who are resistant or intolerant to imatinib
|
Goulden, Scott
|
|
2012
|
13 |
2 |
p. 127-128
2 p.
|
artikel
|
| 27 |
NICE guidance on rituximab for first-line treatment of symptomatic stage III–IV follicular lymphoma in previously untreated patients
|
Doss, Sally
|
|
2012
|
13 |
2 |
p. 128-130
3 p.
|
artikel
|
| 28 |
Nicotine replacement: effective in the long term?
|
Bennet, Neil
|
|
2012
|
13 |
2 |
p. e56-
1 p.
|
artikel
|
| 29 |
Ovarian cancer: breaking the silence
|
The Lancet Oncology,
|
|
2012
|
13 |
2 |
p. 111-
1 p.
|
artikel
|
| 30 |
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine
|
Di Mario, Simona
|
|
2012
|
13 |
2 |
p. e50-
1 p.
|
artikel
|
| 31 |
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine – Author's reply
|
Lehtinen, Matti
|
|
2012
|
13 |
2 |
p. e50-
1 p.
|
artikel
|
| 32 |
Patent expiration offers hope of cheaper cancer drugs
|
Sharma, DC
|
|
2012
|
13 |
2 |
p. e52-
1 p.
|
artikel
|
| 33 |
Persian Gulf states outline regional approach to tackle cancer
|
Burki, Talha Khan
|
|
2012
|
13 |
2 |
p. 126-
1 p.
|
artikel
|
| 34 |
Prediction of post-remission survival in acute myeloid leukaemia: a post-hoc analysis of the AML96 trial
|
Pfirrmann, Markus
|
|
2012
|
13 |
2 |
p. 207-214
8 p.
|
artikel
|
| 35 |
Prostate cancer therapy: finding the right balance
|
Saad, Fred
|
|
2012
|
13 |
2 |
p. 119-120
2 p.
|
artikel
|
| 36 |
PTLD treatment: a step forward, a long way to go
|
Montserrat, Emili
|
|
2012
|
13 |
2 |
p. 120-121
2 p.
|
artikel
|
| 37 |
Qiagen acquires new rights for personalised cancer care
|
Holmes, David
|
|
2012
|
13 |
2 |
p. e55-
1 p.
|
artikel
|
| 38 |
Renaissance of autologous stem cell transplantation for AML?
|
Ferrara, Felicetto
|
|
2012
|
13 |
2 |
p. 121-123
3 p.
|
artikel
|
| 39 |
Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial
|
Trappe, Ralf
|
|
2012
|
13 |
2 |
p. 196-206
11 p.
|
artikel
|
| 40 |
Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials
|
D'Amico, Anthony V
|
|
2012
|
13 |
2 |
p. 189-195
7 p.
|
artikel
|
| 41 |
The developing cancer stem-cell model: clinical challenges and opportunities
|
Vermeulen, Louis
|
|
2012
|
13 |
2 |
p. e83-e89
nvt p.
|
artikel
|
| 42 |
The SCAR project: compassion through reality
|
Loh, Lawrence
|
|
2012
|
13 |
2 |
p. 132-133
2 p.
|
artikel
|
| 43 |
Trial by media
|
Holmes, David
|
|
2012
|
13 |
2 |
p. 133-134
2 p.
|
artikel
|
| 44 |
Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC
|
Caraceni, Augusto
|
|
2012
|
13 |
2 |
p. e58-e68
nvt p.
|
artikel
|
| 45 |
US EPA carcinogens assessment programme under fire
|
Furlow, Bryant
|
|
2012
|
13 |
2 |
p. e56-
1 p.
|
artikel
|
| 46 |
US veterans hospitals lack mammography services
|
Furlow, Bryant
|
|
2012
|
13 |
2 |
p. e57-
1 p.
|
artikel
|
| 47 |
VEGF Trap for the treatment of malignant ascites
|
Becker, Gerhild
|
|
2012
|
13 |
2 |
p. 115-116
2 p.
|
artikel
|
| 48 |
Voices from the front: February
|
Mastrianni, David M
|
|
2012
|
13 |
2 |
p. 134-
1 p.
|
artikel
|
Tijdschrift beschrijving